A ground-breaking research that analysed health data from more than 170,000 adults have found that weight-loss drugs such as Ozempic could slash the risk of developing certain cancers by up to 28 per cent.
The large-scale study found that patients taking GLP-1 receptor agonists—a class of medications that includes Ozempic, Wegovy, and Mounjaro—showed a seven per cent overall reduction in obesity-related cancer risk compared to those on alternative diabetes treatments.
